Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation

W. Arcese, F. R. Mauro, G. Alimena, F. Lo Coco, M. R. De Cuia, M. Screnci, A. P. Iori, E. Montefusco, F. Mandelli

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Eighteen chronic myeloid leukemia patients with hematological (four patients) or only cytogenetic (14 patients) relapse occurring after T cell-depleted allogeneic bone marrow transplantation (BMT) have been treated with alpha 2b interferon (IFN) at a starting dose of 5x106 i.u./m2 subcutaneously three times a week. All four patients with hematological relapse achieved long-lasting hematological remission without reduction of bone marrow Ph1 positive cells. When IFN was started the median percent-age of bone marrow Ph1-possitive metaphases was 50% (range 9-100) for the 14 patients with cytogenetic relapse. Twelve (85.7%) of these patients are alive with a median follow-up of 25 months (range 20-37 months) from cytogenetic relapse and 33 months (range 27-49 months) from BMT. Six (43%) of the 14 patients progressed to hematological relapse and eight patients (57%) are still in hematological remission with two patients achieving complete cytogenetic remission confirmed at molecular level by disappearance of the M-BCR rearranged band. IFN therapy may be a good alternative to conventional chemotherapy for transplanted CML patients with hematological relapse and the treatment of choice for patients with a persistent cytogenetic relapse occurring after T cell-depleted BMT.

Original languageEnglish
Pages (from-to)309-315
Number of pages7
JournalBone Marrow Transplantation
Volume5
Issue number5
Publication statusPublished - 1990

Fingerprint

Homologous Transplantation
Bone Marrow Transplantation
Interferons
T-Lymphocytes
Cytogenetics
Recurrence
Therapeutics
interferon alfa-2b
Bone Marrow
Metaphase
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Arcese, W., Mauro, F. R., Alimena, G., Lo Coco, F., De Cuia, M. R., Screnci, M., ... Mandelli, F. (1990). Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplantation, 5(5), 309-315.

Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation. / Arcese, W.; Mauro, F. R.; Alimena, G.; Lo Coco, F.; De Cuia, M. R.; Screnci, M.; Iori, A. P.; Montefusco, E.; Mandelli, F.

In: Bone Marrow Transplantation, Vol. 5, No. 5, 1990, p. 309-315.

Research output: Contribution to journalArticle

Arcese, W, Mauro, FR, Alimena, G, Lo Coco, F, De Cuia, MR, Screnci, M, Iori, AP, Montefusco, E & Mandelli, F 1990, 'Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation', Bone Marrow Transplantation, vol. 5, no. 5, pp. 309-315.
Arcese, W. ; Mauro, F. R. ; Alimena, G. ; Lo Coco, F. ; De Cuia, M. R. ; Screnci, M. ; Iori, A. P. ; Montefusco, E. ; Mandelli, F. / Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation. In: Bone Marrow Transplantation. 1990 ; Vol. 5, No. 5. pp. 309-315.
@article{df51cc9174254aa9ba80dfb88e6f6914,
title = "Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation",
abstract = "Eighteen chronic myeloid leukemia patients with hematological (four patients) or only cytogenetic (14 patients) relapse occurring after T cell-depleted allogeneic bone marrow transplantation (BMT) have been treated with alpha 2b interferon (IFN) at a starting dose of 5x106 i.u./m2 subcutaneously three times a week. All four patients with hematological relapse achieved long-lasting hematological remission without reduction of bone marrow Ph1 positive cells. When IFN was started the median percent-age of bone marrow Ph1-possitive metaphases was 50{\%} (range 9-100) for the 14 patients with cytogenetic relapse. Twelve (85.7{\%}) of these patients are alive with a median follow-up of 25 months (range 20-37 months) from cytogenetic relapse and 33 months (range 27-49 months) from BMT. Six (43{\%}) of the 14 patients progressed to hematological relapse and eight patients (57{\%}) are still in hematological remission with two patients achieving complete cytogenetic remission confirmed at molecular level by disappearance of the M-BCR rearranged band. IFN therapy may be a good alternative to conventional chemotherapy for transplanted CML patients with hematological relapse and the treatment of choice for patients with a persistent cytogenetic relapse occurring after T cell-depleted BMT.",
author = "W. Arcese and Mauro, {F. R.} and G. Alimena and {Lo Coco}, F. and {De Cuia}, {M. R.} and M. Screnci and Iori, {A. P.} and E. Montefusco and F. Mandelli",
year = "1990",
language = "English",
volume = "5",
pages = "309--315",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation

AU - Arcese, W.

AU - Mauro, F. R.

AU - Alimena, G.

AU - Lo Coco, F.

AU - De Cuia, M. R.

AU - Screnci, M.

AU - Iori, A. P.

AU - Montefusco, E.

AU - Mandelli, F.

PY - 1990

Y1 - 1990

N2 - Eighteen chronic myeloid leukemia patients with hematological (four patients) or only cytogenetic (14 patients) relapse occurring after T cell-depleted allogeneic bone marrow transplantation (BMT) have been treated with alpha 2b interferon (IFN) at a starting dose of 5x106 i.u./m2 subcutaneously three times a week. All four patients with hematological relapse achieved long-lasting hematological remission without reduction of bone marrow Ph1 positive cells. When IFN was started the median percent-age of bone marrow Ph1-possitive metaphases was 50% (range 9-100) for the 14 patients with cytogenetic relapse. Twelve (85.7%) of these patients are alive with a median follow-up of 25 months (range 20-37 months) from cytogenetic relapse and 33 months (range 27-49 months) from BMT. Six (43%) of the 14 patients progressed to hematological relapse and eight patients (57%) are still in hematological remission with two patients achieving complete cytogenetic remission confirmed at molecular level by disappearance of the M-BCR rearranged band. IFN therapy may be a good alternative to conventional chemotherapy for transplanted CML patients with hematological relapse and the treatment of choice for patients with a persistent cytogenetic relapse occurring after T cell-depleted BMT.

AB - Eighteen chronic myeloid leukemia patients with hematological (four patients) or only cytogenetic (14 patients) relapse occurring after T cell-depleted allogeneic bone marrow transplantation (BMT) have been treated with alpha 2b interferon (IFN) at a starting dose of 5x106 i.u./m2 subcutaneously three times a week. All four patients with hematological relapse achieved long-lasting hematological remission without reduction of bone marrow Ph1 positive cells. When IFN was started the median percent-age of bone marrow Ph1-possitive metaphases was 50% (range 9-100) for the 14 patients with cytogenetic relapse. Twelve (85.7%) of these patients are alive with a median follow-up of 25 months (range 20-37 months) from cytogenetic relapse and 33 months (range 27-49 months) from BMT. Six (43%) of the 14 patients progressed to hematological relapse and eight patients (57%) are still in hematological remission with two patients achieving complete cytogenetic remission confirmed at molecular level by disappearance of the M-BCR rearranged band. IFN therapy may be a good alternative to conventional chemotherapy for transplanted CML patients with hematological relapse and the treatment of choice for patients with a persistent cytogenetic relapse occurring after T cell-depleted BMT.

UR - http://www.scopus.com/inward/record.url?scp=0025194702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025194702&partnerID=8YFLogxK

M3 - Article

C2 - 2350627

AN - SCOPUS:0025194702

VL - 5

SP - 309

EP - 315

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -